Asthma is a chronic inflammatory disease of the lungs. The purpose of this review is to discuss and determine if a reduction in severity and number of exacerbations exists between current therapies and the use of monoclonal antibodies in the treatment of severe allergic asthma.
To identify the efficacy of monoclonal antibodies in the treatment of severe allergic asthma uncontrolled with convention therapies, a data base search was performed. This included the National Center for Biotechnology Information, U.S. National Library of Medicine, National Institute of Health, and Medline.
Keywords: asthma, guidelines, diagnosis, treatment, monoclonal antibodies.
Four main studies were chosen for evaluation: INNOVATE, PERSIST, DREAM and Ortega et al studies.
The INNOVATE study is a randomized, double blind study with 419 participants. The PERSIST study involves 158 patients and is a prospective, open label, observational and open-center study.
The mepolizumab studies, Ortega et al and DREAM, were randomized, double-blind study evaluating 576 and 621 patients respectfully.
These studies indicate beneficial results, with omalizumab and mepolizumab therapy, for the patient with severe allergic asthma uncontrolled with conventional therapies.
Asthma is defined as a reversible chronic inflammatory disease of the airways. Conventional treatment of asthma is achievable except for in a small percentage with an allergic asthma phenotype. The INNOVATE, PERSIST, DREAM, and Ortega et al studies show that treatment with a monoclonal antibody reduces exacerbations and improves quality of life. This makes monoclonal antibodies a viable therapy in the allergic asthmatic.
WOLF, ERIC D.
"The Use of Monoclonal Antibodies in the Treatment of Asthma,"
Lynchburg Journal of Medical Science: Vol. 1
, Article 96.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol1/iss3/96
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.